



Riociguat Prevents Fibrotic Tissue Remodelling and Improves Survival in Salt-Sensitive Dahl Rats

Citation

Geschka, Sandra, Axel Kretschmer, Yuliya Sharkovska, Oleg V. Evgenov, Andreas Hucke, Bettina Lawrenz, Berthold Hoher, and Johannes-Peter Stasch. 2011. Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats. BMC Pharmacology 11(Suppl. 1): P28.

Published Version

doi:10.1186/1471-2210-11-S1-P28

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:10400679>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

POSTER PRESENTATION

Open Access

Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats

Sandra Geschka¹, Axel Kretschmer², Yuliya Sharkovska^{3,4}, Oleg V Evgenov⁵, Andreas Hucke¹, Bettina Lawrenz⁶, Berthold Hoher^{3,4}, Johannes-Peter Stasch^{1,7*}

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Halle, Germany. 24-26 June 2011

Background

A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach to the management of various cardiopulmonary disorders associated with endothelial dysfunction. Novel sGC stimulators, including riociguat (BAY 63-2521), have a dual mode of action: they sensitize sGC to endogenously produced nitric oxide (NO) and also directly stimulate sGC independently of NO. Little is known about their effects on tissue remodelling and degeneration and survival in experimental malignant hypertension.

Results

Mortality, hemodynamics and biomarkers of tissue remodelling and degeneration were assessed in Dahl salt-sensitive rats maintained on a high salt diet and treated with riociguat (3 or 10 mg/kg daily) for 14 weeks. Riociguat markedly attenuated systemic hypertension, improved systolic heart function and increased survival (from 33% in the placebo group to 85% in the treated animals). Histological examination of the heart and kidneys revealed that riociguat significantly ameliorated fibrotic tissue remodelling and degeneration. Correspondingly, mRNA expression of the pro-fibrotic biomarkers osteopontin (OPN), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and plasminogen activator inhibitor-1 (PAI-1) in the myocardium and the renal cortex was attenuated by riociguat. In addition, riociguat reduced plasma and urinary levels of OPN, TIMP-1, and PAI-1.

Conclusion

Stimulation of sGC by riociguat markedly improves survival and attenuates systemic hypertension and systolic

dysfunction, as well as fibrotic tissue remodelling in the myocardium and the renal cortex in a rodent model of pressure and volume overload. These findings suggest a therapeutic potential of sGC stimulators in providing organ protection in diseases associated with impaired cardiovascular and renal functions.

Author details

¹Cardiology Research, Bayer HealthCare, Wuppertal, Germany. ²Global Biomarker, Bayer HealthCare, Wuppertal, Germany. ³Institute of Nutritional Science, University of Potsdam, Potsdam, Germany. ⁴Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charité, Berlin, Germany. ⁵Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ⁶Pathology, Bayer HealthCare, Wuppertal, Germany. ⁷Institute of Pharmacy, Martin Luther University, Halle, Germany.

Published: 1 August 2011

doi:10.1186/1471-2210-11-S1-P28

Cite this article as: Geschka et al.: Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats. *BMC Pharmacology* 2011 **11**(Suppl 1):P28.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 **BioMed Central**

* Correspondence: johannes-peter.stasch@bayer.com

¹Cardiology Research, Bayer HealthCare, Wuppertal, Germany

Full list of author information is available at the end of the article